Compare ADMA Biologics Inc (ADMA) vs Ares Capital Corporation (ARCC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Ares Capital Corporation — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Ares Capital Corporation trades at $18.35 (market cap $13.26B). The key difference: Ares Capital Corporation is far larger — about 6.2× ADMA Biologics Inc's market cap, and Ares Capital Corporation pays a 10.4% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ARCC | |
|---|---|---|
Market Cap | $2.13B | $13.26B |
Sector | Health | Financials |
52-Week High | $20.38 | $23.25 |
52-Week Low | $7.60 | $17.45 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 10.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ARCC trades at $18.47, down 1.39% on the day, near its consensus low price target of $18.50. The stock shows neutral technical signals with mixed moving averages and oscillators. Recent quarterly EPS results have missed expectations, though the company maintains a high net income margin of 84.5%. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income-focused strategies.
Outlook remains cautiously optimistic given strong analyst support (24 Buy, 8 Hold) and a $20.58 consensus target implying ~11% upside. Risks include earnings misses and revenue declines from $1.7B in 2024 to a projected $1.4B in 2026. The stock's P/E of 11.39 and P/B of 0.95 suggest reasonable valuation amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →
